We also found that the sequential treatment group induced re-expression or increased expression of the Wnt antagonist genes (SFRP1, HDPR1 and DKK3) in tumor cells of the subcutaneous AML mouse. The gene discussed is DACT1; the disease is acute myeloid leukemia.